羟基脲剂量递增降低坦桑尼亚镰状细胞贫血患儿首次卒中风险(SPHERE):开放标签2期试验
在坦桑尼亚Bugando医疗中心开展的开放标签2期试验纳入202名2-16岁镰状细胞贫血患儿,经颅多普勒筛查后,47例(24%)流速升高者接受羟基脲从20 mg/kg每日一次起始、每8周递增5 mg/kg至最大耐受剂量。12个月后42例配对结果显示经颅多普勒流速从基线182 cm/s降至149 cm/s(p<0.0001),平均下降35 cm/s,无临床卒中发生,35例(83%)恢复正常流速。
要点
- 坦桑尼亚镰状细胞贫血患儿基线经颅多普勒流速升高者占24%(47/196)。
- 羟基脲最大耐受剂量治疗12个月后经颅多普勒流速平均下降35 cm/s(p<0.0001)。
- 42例中35例(83%)经颅多普勒流速恢复正常,无临床卒中发生。
核心结论
- 坦桑尼亚镰状细胞贫血患儿基线卒中风险高;羟基脲最大耐受剂量可显著降低经颅多普勒流速并降低首次卒中风险。
研究设计与样本
- 开放标签2期试验(SPHERE),在坦桑尼亚姆万扎Bugando医疗中心开展。
- 2019年4月24日至2020年4月9日入组202名2-16岁经血红蛋白电泳确诊的镰状细胞贫血患儿,196例经DNA检测确认。
- 经颅多普勒流速升高(条件性170-199 cm/s或异常≥200 cm/s)者接受口服羟基脲20 mg/kg每日一次起始、每8周递增5 mg/kg至最大耐受剂量;流速正常(<170 cm/s)者接受常规诊疗并于12个月后复筛。
- 主要终点为基线至羟基脲治疗12个月后经颅多普勒流速变化,在完成配对测量的患者中分析;安全性在符合方案人群(所有接受研究治疗者)中分析。
主要发现
- 基线筛查时47/196例(24%)经颅多普勒流速升高(条件性43例[22%],异常4例[2%])。
- 45例启动羟基脲,平均起始剂量20.2 mg/kg每日一次(SD 1.4),12个月后平均递增至27.4 mg/kg每日一次(SD 5.1)。
- 42例有基线和12个月配对结果者,经颅多普勒流速从基线平均182 cm/s(SD 12)降至149 cm/s(SD 27),显著低于基线(p<0.0001),平均下降35 cm/s(SD 23)。
- 无临床卒中发生,42例中35例(83%)经颅多普勒流速恢复正常。
- 不良事件轻微,剂量限制性毒性不常见;最常见3级不良事件为疟疾(45例中12例次[29%])和脓毒症(45例中13例次[32%]);3例严重不良事件均与治疗无关,无治疗相关死亡。
关键数值与推荐
- 经颅多普勒流速升高定义为条件性170-199 cm/s或异常≥200 cm/s;正常为<170 cm/s。
- 羟基脲起始剂量20 mg/kg每日一次,每8周递增5 mg/kg每日一次至最大耐受剂量。
临床怎么用
- 作者认为,经颅多普勒筛查联合羟基脲最大耐受剂量是有效的卒中预防策略,支持在撒哈拉以南非洲扩大镰状细胞贫血患者羟基脲的可及性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcranial Doppler screening with chronic transfusions reduces stroke risk in children with sickle cell anaemia but is not feasible in low-resource settings. Hydroxyurea is an alternative treatment to decrease stroke risk. We aimed to estimate stroke risk in children with sickle cell anaemia in Tanzania and to determine the efficacy of hydroxyurea to decrease and prevent stroke. METHODS: We did an open-label, phase 2 trial (SPHERE) at Bugando Medical Centre, Mwanza, Tanzania. Children aged 2-16 years with a diagnosis of sickle cell anaemia confirmed by haemoglobin electrophoresis were eligible for enrolment. Participants had transcranial Doppler ultrasound screening by a local examiner. Participants with elevated Doppler velocities, either conditional (170-199 cm/s) or abnormal (≥200 cm/s), received oral hydroxyurea starting at 20 mg/kg once daily and escalated every 8 weeks by 5 mg/kg per day to the maximum tolerated dose. Participants with normal Doppler velocities (<170 cm/s) received usual care from the sickle cell anaemia clinic and were rescreened after 12 months to determine whether they qualified for treatment on trial. The primary endpoint was change in transcranial Doppler velocity from the baseline visit to after 12 months of hydroxyurea treatment, analysed in all patients who had paired baseline and follow-up measurements collected after 12 months of treatment. Safety was analysed in the per-protocol population (all participants who received study treatment). This study is registered with ClinicalTrials.gov, NCT03948867. FINDINGS: Between April 24, 2019, and April 9, 2020, 202 children were enrolled and had transcranial Doppler screening. Sickle cell anaemia was confirmed by DNA-based testing in 196 participants (mean age 6·8 years [SD 3·5], 103 [53%] were female, and 93 [47%] were male). At the baseline screening, 47 (24%) of 196 participants had elevated transcranial Doppler velocities (43 [22%] conditional, four [2%] abnormal); 45 initiated hydroxyurea at a mean dose of 20·2 mg/kg per day (SD 1·4) with escalation to a mean dose of 27·4 mg/kg per day (5·1) after 12 months. Treatment response was analysed after 12 months (± 1 month; median 11 months, IQR 11-12) and 24 months (±3 months; median 22 months, 22-22). Transcranial Doppler velocities decreased to a mean of 149 cm/s (SD 27) compared with 182 cm/s (12) at baseline, which was significantly lower than baseline (p<0·0001), with an average decline of 35 cm/s (SD 23) after 12 months of treatment in 42 participants with paired results available at baseline and 12 months. No clinical strokes occurred, and 35 (83%) of 42 participants reverted to normal transcranial Doppler velocities. Clinical adverse events were mild, and dose-limiting toxicities were uncommon. The most common grade 3 adverse events were malaria (12 [29%] episodes in 45 patients) and sepsis (13 [32%] episodes). There were three serious adverse events, none of which were treatment-related, and no treatment-related deaths occurred. INTERPRETATION: Children with sickle cell anaemia in Tanzania have a high baseline stroke risk. Hydroxyurea at the maximum tolerated dose significantly lowers transcranial Doppler velocities and reduces primary stroke risk. Transcranial Doppler screening plus hydroxyurea at the maximum tolerated dose is an effective stroke prevention strategy, supporting wider hydroxyurea access for patients with sickle cell anaemia across sub-Saharan Africa. FUNDING: American Society of Hematology, National Institutes of Health, Cincinnati Children's Research Foundation.
引用
- Ambrose EE, Latham TS, Songoro P, et al. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. Lancet Haematol. 2023. PMID: 36870358. doi:10.1016/S2352-3026(22)00405-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。